RMP1 Antibody

What is RMP1-14 antibody and what does it target?

RMP1-14 is a monoclonal antibody that specifically recognizes mouse PD-1 (programmed death-1, also known as CD279), a 50-55 kDa cell surface receptor that belongs to the CD28 family of the immunoglobulin superfamily. PD-1 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and plays a key role in peripheral tolerance and prevention of autoimmune disease in mice. The antibody targets an epitope on mouse PD-1 that blocks the binding of both PD-L1 (B7-H1) and PD-L2 (B7-DC) to PD-1 .

Where is PD-1 expressed and what is its role in immune regulation?

PD-1 is transiently expressed on CD4+ and CD8+ thymocytes, as well as activated T and B lymphocytes and myeloid cells. PD-1 expression typically declines after successful elimination of antigen. At the molecular level, PD-1 signaling inhibits T-cell activation upon binding to its ligands (PD-L1 and PD-L2), which leads to reduced proliferation, decreased cytokine production, and potential T-cell death. This mechanism serves as a negative immunoregulatory pathway that prevents overactivation of immune cells and subsequent inflammatory responses. In knockout models, mice lacking PD-1 develop autoimmune conditions including dilated cardiomyopathy and splenomegaly, demonstrating its critical role in maintaining peripheral tolerance .

What are the primary research applications for RMP1-14 antibody?

The RMP1-14 antibody has been validated for several research applications:

• Flow cytometric analysis: It can be used at concentrations ≤1 μg per test for analyzing PD-1 expression on cell populations

• Blocking experiments: The antibody effectively blocks PD-1 interaction with its ligands PD-L1 and PD-L2

• Functional assays: It inhibits T cell proliferation and cytokine production by blocking the PD-1 inhibitory pathway

• Cancer immunotherapy models: Used in tumor models to enhance anti-tumor immune responses

• Autoimmune disease research: Applied in experimental models such as experimental autoimmune encephalomyelitis (EAE)

For flow cytometry applications, the antibody has been tested on Con A-activated splenocytes, with cell numbers ranging from 10^5 to 10^8 cells per test .

How does RMP1-14 compare to other anti-PD-1 antibodies in blocking efficiency?

Comparative studies between different anti-mouse PD-1 antibodies have revealed significant differences in blocking efficiency. When compared with the 1A12 antibody, RMP1-14 showed lower blocking efficiency for both PD-L1 and PD-L2 binding to PD-1. Specifically:

What is the difference between blocking and agonist anti-PD-1 antibodies?

Anti-PD-1 antibodies can be classified into two functionally distinct categories based on their binding epitopes and mechanisms of action:

• Blocking antibodies (e.g., RMP1-14):

  • Bind to the membrane-distal region of PD-1 (segments #1, #2, and #5)

  • Compete with PD-L1/PD-L2 for binding to PD-1

  • Prevent inhibitory signaling, thereby enhancing T cell function

  • Used primarily in cancer immunotherapy to reinvigorate exhausted T cells

• Agonist antibodies (e.g., HM266):

  • Bind to the membrane-proximal external region (MPER) of PD-1 (segments #7 and #8)

  • Do not interfere with natural ligand binding

  • Trigger PD-1 inhibitory signaling, suppressing T cell function

  • Potentially useful for treating inflammatory and autoimmune diseases

The differential binding sites directly correlate with function – antibodies binding to the membrane-distal region that overlaps with PD-L1 binding sites (residues 66-78 and 128-134) act as blockers, while those binding to MPER act as agonists .

What mechanisms contribute to RMP1-14's therapeutic effects in autoimmune disease models?

RMP1-14 and other anti-PD-1 antibodies can exhibit therapeutic effects in autoimmune disease models through multiple mechanisms:

• Blocking inhibitory signaling: By preventing PD-1/PD-L1 interaction, RMP1-14 can enhance T cell responses against tumors or pathogens .

• Antibody-dependent cellular cytotoxicity (ADCC): Depending on the antibody isotype and Fc region, anti-PD-1 antibodies can mediate depletion of PD-1-expressing activated T cells, which may be beneficial in autoimmune settings.

• Targeted radioisotope delivery: Novel applications include conjugating anti-PD-1 antibodies with radioisotopes (theranostic approach) to both image and deplete pathogenic PD-1+ T cells in models like experimental autoimmune encephalomyelitis (EAE). The 177Lu radioisotope-labeled anti-PD-1 antibody demonstrated significant in vitro cytotoxicity toward activated CD4+PD-1+ T lymphocytes and reduced disease progression in the EAE animal model .

• Modulation of humoral immunity: Treatment with anti-PD-1 antibodies can reduce antigen-specific antibody production, as demonstrated in immunization studies with NP-OVA in alum .

What cell types and activation protocols are recommended for testing RMP1-14 activity?

For optimal evaluation of RMP1-14 activity, researchers should consider the following cell types and activation protocols:

• Splenocytes with Concanavalin A activation: RMP1-14 has been validated on 3-day Con A-activated mouse splenocytes for flow cytometric analysis .

• Cell number optimization: Empirical determination of cell numbers is recommended, with a typical range between 10^5 to 10^8 cells per test in a final volume of 100 μL .

• T cell functional assays: For assessing the blocking activity of RMP1-14, use of the functional grade purified antibody (e.g., Product #16-9982) is recommended over standard formulations .

• Reporter cell systems: To measure PD-1 signaling inhibition, systems incorporating luciferase reporters can effectively demonstrate dose-dependent reversal of PD-1 inhibitory signals by RMP1-14 .

• Activated B cells: Since PD-1 is also expressed on activated B cells, these can serve as additional target cells for evaluating antibody binding and functional effects .

When designing experiments, careful antibody titration is essential for optimal performance. The recommended starting concentration is ≤1 μg per test for flow cytometry applications .

How should researchers handle potential cross-reactivity and specificity concerns?

When using RMP1-14 in complex experimental systems, researchers should address several specificity and cross-reactivity considerations:

• Species specificity: RMP1-14 is specific for mouse PD-1 and does not cross-react with human PD-1. For studies requiring human-mouse cross-reactivity, alternative antibodies or humanized mouse models (such as human PD-1 knock-in mice) should be considered .

• Control experiments: Include appropriate isotype controls (rat IgG2a for the original RMP1-14 or mouse IgG2a for the chimeric RMP1-14-CP157) to control for non-specific binding .

• Blocking controls: To confirm specificity in blocking experiments, researchers should include controls without PD-1 signaling (e.g., cells expressing anti-CD3 scFv without PD-L1) to demonstrate that the antibody works by blocking the PD-1 inhibitory signal rather than through direct T cell stimulation .

• SDS-PAGE migration anomalies: Be aware that despite its predicted molecular weight, PD-1 often migrates at higher molecular weights in SDS-PAGE, which should be considered when validating specificity by Western blot .

• Expression pattern validation: Confirm PD-1 expression patterns on expected cell populations (activated T cells, B cells, subset of double-negative thymocytes) as part of specificity controls .

What are the optimal antibody concentrations and experimental conditions for various applications?

Researchers should optimize RMP1-14 usage based on the specific application:

For optimal results, antibody purity should be >90% as determined by SDS-PAGE, with aggregation <10% as determined by HPLC. The antibody formulation typically includes 0.2 μm post-manufacturing filtration to ensure quality .

What are the differences between original RMP1-14 and its chimeric/recombinant versions?

Several engineered variants of the RMP1-14 antibody exist, each with specific structural modifications:

• Original RMP1-14: A rat IgG2a monoclonal antibody that binds to mouse PD-1 and blocks interaction with its ligands .

• RMP1-14-CP157 (Chimeric): This variant maintains identical variable domain sequences to the original RMP1-14 but has the constant region sequences switched from rat IgG2a to mouse IgG2a. This chimeric version maintains the same functional properties as the original but with potentially reduced immunogenicity in mouse models due to the mouse constant regions .

• Murinized RMP1-14: A recombinant version with mouse-derived constant regions, purified using multi-step affinity chromatography methods such as Protein A or G. This engineering approach helps minimize anti-rat antibody responses in long-term mouse studies .

• LALAPG Variant: A modified version containing mutations in the Fc region that reduce binding to Fcγ receptors, thereby minimizing effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This version is useful when researchers want to study PD-1 blockade effects without the confounding variable of Fc-mediated effector functions .

These engineering approaches allow researchers to select the most appropriate RMP1-14 variant based on specific experimental needs, particularly for in vivo studies where immunogenicity and effector functions are important considerations.

How do the Fc region differences in RMP1-14 variants affect experimental outcomes?

The Fc region of antibodies significantly influences their in vivo activity through interactions with Fc receptors on immune cells. For RMP1-14 variants, these differences can substantially impact experimental outcomes:

• Original RMP1-14 (rat IgG2a):

  • Binds mouse Fcγ receptors with moderate affinity

  • Can mediate some degree of ADCC and CDC

  • May cause anti-rat antibody responses in long-term mouse studies

• RMP1-14-CP157 (mouse IgG2a constant regions):

  • Improved binding to mouse Fcγ receptors compared to rat IgG2a

  • Enhanced effector functions in mouse models

  • Reduced immunogenicity in mice, allowing for longer treatment schedules

• LALAPG Variant:

  • Contains L234A, L235A, and P329G mutations in the Fc region

  • Significantly reduced binding to Fcγ receptors

  • Minimal effector functions (ADCC, CDC)

  • Useful for isolating the effects of PD-1 blockade without Fc-mediated effects

In research applications, these differences become critical when:

• Studying long-term treatment effects where immunogenicity could confound results

• Investigating whether therapeutic effects are due to signaling blockade or cell depletion

• Developing therapeutic approaches where selective cell depletion or preservation is desired

Researchers should select the appropriate variant based on whether Fc-mediated functions would benefit or confound their experimental outcomes .

How does RMP1-14 compare to other anti-PD-1 antibodies in binding affinity and functional assays?

Different anti-mouse PD-1 antibodies exhibit significant variations in binding affinity and functional activity:

In reporter assay systems measuring functional activity, 1A12 increased luciferase induction (indicating blockade of PD-1 inhibitory signals) with an IC50 of 0.28 μg/mL, while RMP1-14 showed a maximal induction of fivefold with an IC50 of 1.99 μg/mL. These functional differences directly correlate with their binding affinity and capacity to block PD-1/PD-L interactions .

What are the key differences between anti-PD-1 antibodies that act as agonists versus antagonists?

Anti-PD-1 antibodies can be functionally classified as either antagonists (blockers) or agonists based on their binding epitopes and resulting effects:

Antagonist/Blocking Antibodies (e.g., RMP1-14):

• Bind to membrane-distal regions of PD-1 (segments #1, #2, and #5)

• Compete with PD-L1/PD-L2 for binding to PD-1

• Prevent inhibitory signaling through PD-1

• Enhance T cell proliferation and cytokine production

• Primary application: Cancer immunotherapy

Agonist Antibodies (e.g., HM266):

• Bind to membrane-proximal external region (MPER) (segments #7 and #8)

• Do not interfere with natural ligand binding

• Actively trigger PD-1 inhibitory signaling

• Suppress T cell activation and inflammatory responses

• Primary application: Autoimmune and inflammatory diseases

The binding location is crucial for function - antibodies binding to membrane-distal regions that overlap with PD-L1 binding sites act as blockers, while those binding to MPER regions act as agonists. The agonist antibodies' activity is often enhanced when engineered with increased binding to FcγRIIB, which facilitates crosslinking of PD-1 molecules and subsequent signal transduction .

How are radioactively labeled anti-PD-1 antibodies being used in theranostic approaches?

A novel application of anti-PD-1 antibodies involves labeling them with radioisotopes for both diagnostic imaging and therapeutic targeting of activated T cells in autoimmune diseases. This theranostic approach has shown promising results in experimental models:

• Diagnostic imaging applications: Anti-PD-1 antibodies labeled with positron-emitting radioisotopes enable positron-emission tomography/computed tomography (PET/CT) imaging of activated PD-1+ T cells. This has successfully visualized lymphocyte accumulation in cervical draining lymph nodes in experimental autoimmune encephalomyelitis (EAE) models, providing a non-invasive method to monitor T cell activation in autoimmune diseases .

• Therapeutic targeting: The same antibodies labeled with beta-emitting radioisotopes like Lutetium-177 (177Lu) can selectively deplete activated, potentially pathogenic PD-1+ T lymphocytes. In vitro studies demonstrated significant cytotoxicity toward activated CD4+PD-1+ T cells, while in vivo application in the EAE model showed reduced disease progression .

This dual-purpose approach offers several advantages over conventional immunotherapies:

• Selective targeting of activated T cells rather than broad immunosuppression

• Potential monitoring of treatment response via imaging

• Spatial and temporal control of therapeutic effect

Such approaches represent a significant advancement in precision medicine for autoimmune disorders, potentially allowing for more targeted intervention with fewer systemic side effects .

What role does RMP1-14 play in studying tumor microenvironment and cancer immunotherapy?

RMP1-14 has become an important tool in cancer immunology research, particularly for studying the PD-1/PD-L1 axis in tumor microenvironments:

• Tumor immune evasion studies: Many tumors upregulate PD-L1 expression, creating an immunosuppressive microenvironment. RMP1-14 helps researchers model how blocking the PD-1/PD-L1 interaction can reverse this immune evasion mechanism. Studies have shown that tumors expressing high levels of PD-L1 (including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma) exhibit increased resistance to CD8 T cell-mediated lysis, which can be counteracted with PD-1 blocking antibodies .

• Preclinical cancer models: In mouse models of melanoma, treatment with antibodies that block PD-1/PD-L1 interaction (including RMP1-14) has been shown to transiently arrest tumor growth. These preclinical studies have been crucial in developing the rationale for human anti-PD-1 therapies now widely used in cancer treatment .

• Combination therapy research: RMP1-14 is frequently used to investigate how PD-1 blockade can be combined with other immunotherapeutic approaches, radiation therapy, or targeted therapies to enhance anti-tumor immunity and overcome resistance mechanisms.

• Immune cell profiling: The antibody helps researchers characterize changes in PD-1 expression on tumor-infiltrating lymphocytes, providing insights into T cell exhaustion and potential predictive biomarkers for immunotherapy response.

These applications make RMP1-14 an essential reagent for advancing our understanding of cancer immunology and developing improved immunotherapeutic strategies .